Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-04-17
1993-03-30
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31415
Patent
active
051984571
ABSTRACT:
The use of 1-(thienylalkyl)imidazole-2-thione derivatives as antihyperthyroid agents are described herein. These compounds may be administered as a preparatory adjunct procedure when thyroidectomy or radioactive iodine therapy is the recommended therapy or as a primary therapy when surgical procedures is not recommended or long term therapy is advisabe.
REFERENCES:
patent: 5057613 (1991-10-01), Matthews et al.
Ray W. Fuller, et al., New Inhibitors of Dopamine .beta.-Hydroxylase, Advances in Enzyme Regulation, 1977, V15, pp. 267-281.
Fay Zohreh A.
Merrell Dow Pharmaceuticals Inc.
Simmons Edlyn S.
Waddell Frederick E.
LandOfFree
Treatment of hyperthyroidism with 1,3-dihydro-1[2-(2-thienyl)alk does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of hyperthyroidism with 1,3-dihydro-1[2-(2-thienyl)alk, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hyperthyroidism with 1,3-dihydro-1[2-(2-thienyl)alk will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1281274